Mitogen-activated protein kinase (MAPK) activation is a common property of human cancers
and is often due to activating mutations in the BRAF and RAS genes. BRAF kinase domain …

Abstract Mitogen Activated Protein Kinase (MAPK) pathway activation is a frequent event in
human cancer and is often the result of activating mutations in the BRAF and RAS …

Tumors with mutations in the gene encoding the serine-threonine protein kinase BRAF are
dependent on the MAPK signaling pathway for their growth, what offers an opportunity to test …

Constitutive ERK activation is a common finding in human cancer and is often the result of
activating mutations of BRAF and RAS. BRAF missense mutations occur in approximately …

The mitogen-activated protein kinase (MAPK) pathway is essential for cellular proliferation,
growth, and survival. Constitutive activation of this pathway by BRAF mutations can cause …

Abstract The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …

Activating mutations of the BRAF oncogene are present in approximately 5-10% of all
human malignancies and lead to constitutive activation of the mitogen activated protein …

The identification of mutationally activated BRAF in many cancers altered our conception of
the part played by the RAF family of protein kinases in oncogenesis. In this Review, we …

Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered
as being most prevalent in melanoma in 2002. Only recently have potent and selective …

With the identification of activating mutations in BRAF across a wide variety of malignancies,
substantial effort was placed in designing safe and effective therapeutic strategies to target …